A COMPARATIVE EVALUATION OF THE HEALTH ECONOMIC OUTCOMES OF FEBUXOSTAT AND ALLOPURINOL IN GOUT PATIENTS WITH CHRONIC KIDNEY DISEASE

被引：0
|
作者：
Mitri, G. [1 ]
Wittbrodt, E. T. [1 ]
Turpin, R. S. [1 ]
Costa, L. A. [2 ]
Schulman, K. [2 ]
机构：
[1] Takeda Pharmaceut Inc, Med Affairs, Deerfield, IL USA
[2] Outcomes Res Solut Inc, Shrewsbury, MA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷
关键词：
D O I：
10.1136/annrheumdis-2014-eular.1625
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0174
引用
收藏
页码：445 / 445
页数：1
相关论文
共 50 条
  • [1] Cardiovascular Outcomes of Treatment with Febuxostat and Allopurinol in Gout Patients with Kidney Disease
    White, William B.
    Gunawardhana, Lhanoo
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [2] Efficacy and Safety of Allopurinol and Febuxostat in Patients with Gout and Chronic Kidney Disease: A Subgroup Analysis of the STOP Gout Study
    Helget, Lindsay
    Davis-Karim, Anne
    O'Dell, James
    Mikuls, Ted
    Newcomb, Jeff
    Androsenko, Maria
    Brophy, Mary
    England, Bryant
    Ferguson, Ryan
    Pillinger, Michael
    Neogi, Tuhina
    Wu, Hongsheng
    Palevsky, Paul
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3616 - 3618
  • [3] Comparative Cardiovascular Risks of Febuxostat and Allopurinol in Patients with Diabetes Mellitus and Chronic Kidney Disease
    Huang, Hsin Hsiang
    Chen, Yun-Yi
    Fang, Yu-Wei
    Liou, Hung-Hsiang
    Wang, Jing-Tong
    Tsai, Ming-Hsein
    MEDICAL SCIENCE MONITOR, 2024, 30
  • [4] MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH RECURRENT GOUT, CARDIOVASCULAR AND CHRONIC KIDNEY DISEASE, INITIATING ON ALLOPURINOL OR FEBUXOSTAT
    Foody, J.
    Turpin, R.
    Tidwell, B. A.
    Lawrence, D. F. Eisenberg
    Schulman, K. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 374 - 374
  • [5] Febuxostat or Allopurinol in Patients with Gout Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)
    Alten, R.
    Mischkewitz, M.
    Nitschmann, S.
    INTERNIST, 2020, 61 (05): : 530 - 532
  • [6] Febuxostat was Better than Allopurinol in Patients with Advanced Chronic Kidney Disease
    Hao, Zhen-Ye
    Qiao, Peng-Yan
    Wei, James Cheng-Chung
    Zhang, Li-Yun
    AMERICAN JOURNAL OF MEDICINE, 2025, 138 (04): : e68 - e68
  • [7] Major Cardiovascular Events in Gout Patients with Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating on Allopurinol or Febuxostat (Uloric)
    Foody, JoAnne
    Turpin, Robin
    Tidwell, Beni
    Schulman, Kathy
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [8] Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review
    Anna M. Hu
    Jamie N. Brown
    Clinical Rheumatology, 2020, 39 : 3287 - 3294
  • [9] Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review
    Hu, Anna M.
    Brown, Jamie N.
    CLINICAL RHEUMATOLOGY, 2020, 39 (11) : 3287 - 3294
  • [10] A STUDY OF ALLOPURINOL USE IN PATIENTS WITH GOUT AND CHRONIC KIDNEY DISEASE
    Sukhdeo, A.
    Sturgess, A.
    INTERNAL MEDICINE JOURNAL, 2014, 44 : 11 - 12
12345